ReviewKeynotePharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase
Cited by (0)
Ming-Hai Wang is an Amarillo Community Endowed Chair in Cancer Biology Research and Director of the Cancer Biology Research Center at School of Pharmacy of the Texas Tech University Health Sciences Center. Dr Wang also is a tenured professor in the Department of Pharmaceutical Sciences in this institution. For the past 30 years, Dr Wang has focused his research on the pathogenesis of RON receptor tyrosine kinase in colon, breast, and pancreatic cancers, with emphasis on the clinical development of RON-targeted biotherapeutics, such as antibody–drug conjugates. Dr Wang has published extensively on these topics and has presented his research findings at various conferences across the world.
Hang-Ping Yao is a senior investigator in the State Key Laboratory for Diagnosis and Treatment of Infectious Diseases and the National Clinical Research Center for Infectious Diseases in the First Affiliated Hospital of Zhejiang University School of Medicine in Hangzhou of China. Dr Yao’s research is focused on the innovative development of antibody-based biotherapeutics for cancer diagnosis and treatment. In addition, he is interested in the molecular mechanisms of immune response to viral infections and the study of vaccines against emerging infectious diseases. Dr Yao has published extensively on both fields and his studies have been awarded with several prestigious national prizes in China.